Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | GSK3A | P49840 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.41 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 3/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL339413 | 0.88 | KDM4E (0.44) | GSK3BKDM4EGSK3ADYRK1ACLK4 | |
| SCHEMBL13657994 | 0.80 | GSK3B (0.40) | GSK3BKDM4EGSK3ADYRK1ACLK4 | |
| SCHEMBL340211 | 0.79 | DPP4 (0.49) | GSK3BEGLN2DPP4DPP8 | |
| SCHEMBL1911506 | 0.78 | EGLN2 (0.41) | GSK3BKDM4EEGLN2LMNAPOLB | |
| SCHEMBL339356 | 0.77 | GSK3B (0.43) | GSK3BKDM4EGSK3ADYRK1ACLK4 | |
| SCHEMBL339104 | 0.73 | KDM4E (0.45) | GSK3BKDM4EEGLN2HPGDHSD17B10 | |
| SCHEMBL340316 | 0.73 | DPP4 (0.48) | GSK3BEGLN2DPP4DPP8 | |
| SCHEMBL3256963 | 0.71 | GSK3A (0.48) | GSK3BKDM4EGSK3ADYRK1ACLK4 | |
| SCHEMBL1911503 | 0.70 | EGLN2 (0.40) | GSK3BKDM4EEGLN2LMNAMEN1 | |
| SCHEMBL339783 | 0.70 | PIK3CA (0.44) | GSK3BKDM4EGSK3ADYRK1ACLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077787-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-03-29 | — | — | US | disclosed |
| US-20120077787-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-03-29 | — | — | US | disclosed |
| US-8097617-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-01-17 | — | — | US | disclosed |
| US-8097617-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-01-17 | — | — | US | disclosed |
| US-20090253689-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-10-08 | — | — | US | disclosed |
| US-20090253689-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-10-08 | — | — | US | disclosed |
| EP-2004643-A1 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007113226-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007113226-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077787-A1 | ORGANIC COMPOUNDS | OAT, GPR119, OTC | GSK3B 2067/4885KDM4E 3759/4885GSK3A 2382/4885 |
| US-20090253689-A1 | Organic Compounds | OAT, GPR119, OTC | GSK3B 2067/4885KDM4E 3759/4885GSK3A 2382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.